Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
D'Aveni-Piney, Maud
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy	Recruiting	3	210	Europe	MC0518, BAT	medac GmbH	Steroid-refractory Acute Graft-versus-host Disease	08/27	08/30
GFM, NCT05226455: Venetoclax in Patients With MDS or AML in Relapse After AHSCT	Recruiting	1/2	55	Europe	venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza	Groupe Francophone des Myelodysplasies, AbbVie	MDS, AML	09/25	03/26
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes	Recruiting	1/2	36	Europe	Onureg + Venetoclax, CC-486 + ABT-199	Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie	Untreated Myelodysplastic Syndrome	11/25	11/28
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA	Recruiting	1/2	150	Europe	Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa	Groupe Francophone des Myelodysplasies, Celgene	MDS, Myelodysplastic Syndromes	05/27	11/27